The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Shares of Roivant (NASDAQ:ROIV) rose 6% in premarket trading Tuesday after the biotech group announced a $1.5B share buyback program and released positive data for its drug brepocitinib.

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million. Pulmovant is tasked ...

We recently compiled a list of 10 Best Stocks Under $15 To Buy Now. In this article, we will look at where Roivant Sciences ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares closed yesterday at $11.76. According to TipRanks, Werber is a 5 ...